Natural cytotoxicity triggering receptor 3–B7-H6 interaction (NKp30–B7-H6)

The NKp30–B7-H6 interaction is a critical immune checkpoint axis involving the activating receptor NKp30 (NCR3), primarily expressed on natural killer (NK) cells, and its tumor-associated ligand B7-H6 (NCR3LG1). While B7-H6 is generally absent from healthy tissues, it is frequently overexpressed on the surface of various hematologic and solid tumors, making it a highly specific target for cancer immunotherapy. Binding of B7-H6 to NKp30 triggers NK cell degranulation and the release of pro-inflammatory cytokines like IFN-gamma, leading to the direct lysis of malignant cells. However, tumors often evade this response by shedding B7-H6 into a soluble form (sB7-H6), which acts as a decoy and induces NK cell desensitization. Current drug development efforts focus on leveraging this interaction through B7-H6-targeted CAR-T cells, bispecific engagers, and monoclonal antibodies designed to restore or enhance the anti-tumor activity of the innate immune system.

Other names

NKp30–NCR3LG1 interactionNCR3–B7-H6 axisCD337–B7-H6 interactionNatural killer cell p30–B7 homolog 6 interaction

Therapeutic strategies targeting this interaction typically involve activating NK cells through the NKp30 receptor upon binding to B7-H6 on tumor cells, or utilizing B7-H6 as a tumor-specific antigen for CAR-T or bispecific antibody-mediated redirection of effector cells. Some approaches also aim to neutralize soluble B7-H6 (sB7-H6) which acts as a decoy to prevent NK cell activation.